Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific (TMO) reported an insider transaction by EVP & COO Michel Lagarde. On 11/13/2025, he exercised 4,638 stock options at $253.99 per share (code M), acquiring common stock, and then sold 4,638 shares at a $594.42 weighted average price (code S). Following these transactions, his directly held common stock was 23,479.909 shares. The sale price reflected multiple trades between $594.36 and $594.88. The option, with a $253.99 exercise price, was originally scheduled to vest in four equal installments on February 26 of 2020–2023 and carried an expiration of 02/26/2026.
TMO: A holder filed a Form 144 notice to sell up to 4,638 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025.
The filing lists an aggregate market value of 2,756,934.94 for the proposed shares and notes 375,708,059 shares outstanding. The shares to be sold were acquired via an option granted on 02/26/2019 and paid in cash on 11/13/2025.
Thermo Fisher Scientific (TMO) received a Form 144 notice for a proposed sale of up to 1,058 common shares through Fidelity Brokerage Services, with an aggregate market value of $622,135.54. The shares are expected to be sold on the NYSE around 11/12/2025.
The securities were acquired via restricted stock vesting: 1,016 shares on 02/23/2022 and 42 shares on 08/25/2023. A related table shows 10,225 common shares were sold on 11/07/2025 for gross proceeds of $5,844,850.08. Shares outstanding were 375,708,059.
Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.
Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.
Thermo Fisher Scientific (TMO) reported insider transactions by an officer (Sr. VP and Chief HR Officer) on 11/07/2025. The filer sold 1,750 shares of common stock at $571.3977, exercised 8,475 stock options at $253.99, and sold 8,475 shares at $571.6701. Following these trades, the filer directly owned 14,144.804 shares.
The exercised option related to a grant that vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
Thermo Fisher Scientific (TMO) insider Gianluca Pettiti filed a Form 144 to sell up to 2,975 shares of common stock on or about 11/10/2025 on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $1,725,500. The shares derive from options granted in 2019 and indicate cash exercise on 11/10/2025. The notice also reports a prior sale of 400 shares on 10/24/2025 for $229,660. Shares outstanding were 375,708,059, a baseline figure.
Thermo Fisher Scientific (TMO) filed a Form 144 notice for a proposed sale of common stock by an affiliated holder. The filing lists 10,225 shares to be sold with an aggregate market value of $5,844,850.08, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/07/2025.
The shares come from a mix of equity awards, including 8,475 shares from an option granted on 02/26/2019 (paid in cash on 11/07/2025) and multiple restricted stock vestings totaling 1,750 shares from 2021–2024. As context, shares outstanding were 375,708,059 at the time referenced in the notice; this is a baseline figure, not the amount being offered.
Thermo Fisher Scientific (TMO) reported Q3 2025 results. Total revenues were $11,122 million, up from $10,598 million a year ago, with product revenue at $6,489 million and service revenue at $4,633 million. Diluted EPS was $4.27 versus $4.25, and operating income reached $1,941 million.
Year to date, operating cash flow was $4,361 million versus $5,377 million in 2024, reflecting working capital outflows. The balance sheet shows cash and equivalents of $1,982 million and long-term obligations of $31,857 million. The company issued additional senior notes in October totaling $2,500 million. Remaining performance obligations were $26.46 billion, with approximately 53% expected to be recognized within 12 months.
By business in Q3: Life Sciences Solutions revenue was $2,588 million, Analytical Instruments $1,893 million, Specialty Diagnostics $1,174 million, and Laboratory Products and Biopharma Services $5,970 million. The company recorded $135 million of restructuring and other costs in Q3 ($316 million year to date) and actions in 2025 affected about 4% of its workforce. Share repurchases were $2,963 million year to date; dividends paid were $474 million.
Thermo Fisher Scientific (TMO) announced a definitive agreement to acquire Clario Holdings for approximately $8.875 billion in cash at closing, plus $125 million in deferred consideration and up to $400 million in contingent consideration. The transaction is expected to close by the middle of 2026, subject to customary closing conditions and regulatory approvals.
This deal adds a significant clinical research and data-focused asset to Thermo Fisher’s portfolio. The consideration structure mixes upfront cash with deferred and contingent payments, aligning part of the price to post‑closing outcomes. The company noted typical regulatory and integration risks and referenced risk factors in its latest periodic reports.
Thermo Fisher Scientific (TMO) disclosed a routine insider transaction on Form 4. Executive Vice President Gianluca Pettiti sold 400 shares of common stock on 10/24/2025 at $574.15 per share (transaction code S). After the sale, he beneficially owned 21,152.223 shares, held directly. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2025.